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Two deacetyl-thymosin 1 analogues containi__g Syntheses of two deacetyl-
Phe (4Br) or D-Phe (4Br) residue--[D-Phe(4Br)21]
deacetyl-thymosin 1 and [Phe(4Br)21]deacetyl- thymosin 1 analogues and their
thymosin cz, respectively--were synthesized by effects on low E-rosette-forming the manual solid-phase method and their immu-
nological effects on the low E-rosette-forming lymphocytes of uraemic patients
lymphocytes of uraemic patients were examined.
One of the synthetic analogues, [Phe(4Br)2deace
tyl-thymosin cz, demonstrated a restorative effect
on the low E-rosette-forming lymphocytes of T. AbikocA and H. Sekino
uraemic patients, which was stronger than that
of deacetyl-thymosin , but the other analogue,
[D-Phe(4Br)21]deacetyl-thymosin 1, showed no Kidney Research Laboratory, Kojinkai, 1-6
restorative effect under the same conditions. Tsutsujigaoka 2-chome, Miyagino-ku, Sendal 980,
Japan
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restorative activity of low E-rosette-forming lym- Abbreviations phocytes.
4 Interestingly, fluorination of the para-
Z, benzyloxycarbonyl; OBzl, benzyl ester; Boc, position of Phe (position 21) resulted in a
tert-butoxycarbonyl; DCC, N,N’-dicyclohex- marked restorative effect on the low E-rosette-
ylcarbodiimide; HOBT, N-hydroxybenzotriazole; forming lymphocytes of uraemic patients com-
DMF, dimethylformamide; E-rosette, a rosette pared with that of [Phe2]deacetyl-thymosin 1.
4
with sheep elTthrocytes; TFA, trifluoroacetic acid; These results prompted us to synthesize two
Phe(4Br), />bromophenylalanine; Et3N, triethyla- deacetyl-thymosin analogues containing bro-
mine; AcOH, acetic acid; PBS, phosphate-buff minated aromatic tings which influence electron-
fered saline; GVB
2+ gelatin veronal buffer; intensity on aromatic tings such as fluorinated
HPLC, high-performance liquid chromatography; ones.
TLC, thin-layer chromatography; Ac, acetyl; EtOH, This paper deals with the solid-phase synth-
ethanol; FAB-MS, fast atom bombardment mass eses of [D-Phe(4Br)2]deacetyl-thymosin and
spectrometry; Bzl, benzyl. [Phe(4Br)2]deacetyl-thymosin a and an exam-
ination of the immunological effect of two ana-
Introduction logues, /Phe(4F)2]deacetyl-thymosin and
deacetyl-thymosin cq, on the low E-rosette-
Thymosin , a peptide containing 28 amino forming lymphocytes of uraemic patients.3’4
acid residues, was isolated by Goldstein et aL
from thyrnosin fraction 5, a mixture of peptides Materials and Methods from calf thymus. Thymosin cq was found to be
active in some of the in vitro tests used for thy- Resin, amino acid derivatives and reagents: The
mosin fraction 5,
2 and it was considered to be chloromethylated polystyrene resin crosslinked
one of the factors that modulated steps in the with 2% divinylbenzene (C1 content 2 retool/g)
maturation of T-lymphocyZ.es. 1’2 and Boc-amino acids, Boc-Ser(Bzl)-OH, Boc-
In our earlier papers,3’ we have demonstrated Asp(OBzl)-OH, Boc-Ala-OH, Boc-Val-OH, Boc-
that not only our synthetic deacetyl-thymosin 1 Thr(Bzl)-OH, Boc-Glu(OBzl)-OH, Boc-Ile-OH,
but also its two synthetic analogues, [Phe21]de Boc-Lys(Z)-OH, Boc-Leu-OH, Boc-Asn-OH, Boc-
acetyl-thymosin and [Phe(4F)2]deacetyl-thy- D-Phe(4Br)-OH and Boc-Phe(4Br)-OH, were
mosin 1 exhibit restorative activity on low E-
rosette-forming lymphocytes of uraemic patients.
21 The synthetic [Phe ]deacetyl-thymosin cz was
Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-
approximately equal in potency to our synthetic
deacetyl-thymosin in uraemic patients.
4 We 20
also found that the acetyl group at the N-terminal ,u-=-u-,-=-u-w-v-u-u---n-o
Ser residue of thymosin 0q is not required for FIG. 1. Amino acid sequence of thymosin
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purchased from Protein Research Inc. (Mino,
Osaka, Japan), Kokusan Chemical Works Ltd
(Kyoto, Japan) and Bachem Feinchemikalain AG.
Solvents were freshly distilled. The purified syn-
thetic [D-Phe(4Br)i1]deacetyl-thymosin and
[Phe-(4Br)2]deacetyl-thymosin (1 were chroma-
tographed on cellulose plates (Merck). Rf values
refer to BuOH-AcOH-H20 (4:1:5, upper layer)
and Rf
2 values refer to BuOH-pyridine-AcOH-H20
(30:20:6:24). Amino acid analysis was performed
by the Hitachi Model 835-50 amino acid analyser.
HPLC was conducted with a Shimadzu LC-9A
apparatus coupled to an analytical YMC-AM-312
column (6.0 x 150 cm). FAB-MS spectrum was
obtained on a Auto Spec Q with an OPUS data
processor. FIG. 2. Purification of synthetic [D-Phe(4Br)21]deacetyl-thymosin
1 by gel-filtration chromatography on a Sephadex G-25 column.
Patient selection: Four uraemic patients who
were suffering from recurrent infectious diseases
were selected. Venous blood was obtained from solution was treated with Amberlite CG-4B
these uraemic patients for the E-rosette forma- (acetate form, approximately 2 g) for 30 min and
tion test. Venous blood samples from two filtered by suction. The filtrate was adjusted to
healthy donors were used as a control, pH 8.0 with 1 N NH4OH and stirred in an ice-
bath for 30 min to reverse a possible N -
0
Solid-phase peptide synthesis: Solid-phase peptide shift at the Ser and Thr residues. The pH of the
syntheses of [D-Phe(4Br)a]deacetyl-thymosin a solution was adjusted to pH 6.0 with a few drops
and [Phe(4Br)a1]deacetyl-thymosin a were of 1 N AcOH, and the solution was lyophilized.
carried out manually in a glass vessel by a step- The residue was dissolved in 2% AcOH (2 ml),
wise strategy starting with Boc-Asn-resin (0.18 applied to a column of Sephadex G-25 (2.8 x
mmol/g, 1 g). 97 cm), and eluted with the same solvent. Frac-
The general procedure for each synthetic cycle tions of 4 ml each were collected per 15 min,
was: (1) three washings with CH2C12; (2) pre- and the absorption at 260 nm was determined
washing with 40% TFA in CH2C12; (3) deprotec- (see Fig. 2). Fractions corresponding to the front
tion for 30 min with TFA in CH2C12; (4) three main peak (robe nos 56-64)were combined and
washings with CHIC12 (5) prewashing with EtN the solvent was removed by evaporation. Analysis
in CH2C12; (6) neutralization for 10 min with 10% by TLC revealed the presence of three ninhydrin-
EtN in CH2C12; (7) three washings with CH2C12; positive spots with Rf 0.11 (main), 0.28 (minor)
(8) addition of 4 eq Boc-amino acid, HOBT and and 0.36 (minor). The crude product was dis-
DCC respectively; (9) reaction for 120 min in solved in a small amount of water and subjected
DMF or N-methyl-2-pyrrolidone + DMF (1:1); to preparative TLC (cellulose plate, 20 x 40 cm)
(10) three washings each with CH2C12, 509/o using the upper layer of BuOH-AcOH-H20
EtOH in CH2C12, DMF and then CH2C12. Double (4:1:5) as a developing solvent. The zone corre-
couplings were done when necessary as judged sponding to Rf 0.11 was separated and extracted
by the ninhydrin test. A triple coupling was only with 2% AcOH. The extracts were concentrated,
necessary for lie; (11) 0.4 M acetylimidazole in applied to a column of Sephadex G-25 (2.8 x
DMF (1 x, 30 min); (12) two washings with 97 cm), and aluted with 2% AcOH as already
DMF and two washings with CH2C|2. described: yield 5.6% based on the starting resin,
The protected peptide resin was treated with [al 80.9 (c 0.4, 2% AcOH), Rf 0.11, Rf
anhydrous hydrogen fluoride containing 10% 0.15, single ninhydrin- and chlorine-tolidine posi-
anisole at 0C for 60 min. After evaporation of tive spot. The synthetic peptide exhibited a single
excess hydrogen fluoride under vacuum, the spot on a paper electrophoresis; Toyo Roshi No.
crude peptide was extracted with 10% AcOH and 51 (2 x 40 cm), pyridinium-acetate buffer at pH
the extract was washed with ether and then eva- 7.3, mobility 2.5 cm from the origin toward the
porated to dryness under vacuum, anode after running at 2 mA, 650 V for 90 min.
Amino acid ratios in a 6 N HCl hydrolysate: Ile
Purification ofdeprotected [D-Phe(4Br)a/deace- 1.00, Ala 3.03, Leu 1.01, Val 1.94, Ser 2.85, Thr
yl-thymosin a: The deprotected crude octaeico- 2.88, D-Phe(4Br) 0.93, Asp 3.90, Glu 5.87, Lys
sapeptide was dissolved in H20 (5 ml). The 4.02 (recovery of lle 86%). The synthetic peptide
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sion of sheep erythrocytes (0.5 ml) and incu-
bated for 12 h at 4C. The mixture was then
centrifuged for 5 min at 900 rpm. Triplicate wet-
cell preparations were checked by phase-contrast
microscopy. For each preparation, 200 lympho-
cytes were counted, and the proportion binding
more than three erythrocytes was determined.
FIG. 3. HPLC profiles of (A)[D-Phe(4Br)21]deacetyl-thymosin 1 Results and Discussion and (B) [Phe(4Br)21]deacetyl-thymosin c1.
In vitro incubation of human peripheral blood
exhibited a single peak on HPLC using an analy- lymphocytes from uraemic patients suffering
tical YMC AM-312 column (6.0 x 150 mm) at a from impaired immunological function with thy-
retention time of 11.95 min (A), when eluted mosin a increases the percentage of E-rosette
with a gradient of acetonitrile 25 to 45% in 0.1% formation.3’4 In our previous paper,
4 we reported
TFA at a flow rate of 1 ml per min (Fig. 3). FAB- that incubation of peripheral venous blood lym-
MS m/z: calculated (M + H) + 3163, observed phocytes from uraemic patients in the presence
(M + H) + 3162. of various amounts of the two synthetic analo-
gues, [Phe(4F)21] deacetyl-thymosin and
Purification of deprotected [Phe(4Br)al]deace- [Phe21]deacetyl-thymosin al, from 0.1 to 10.0 l.tg/
yl-thymosin al: The purification procedure of ml resulted in the recovery of E-rosette forma-
the deprotected crude [Phe(4Br)a]deacetyl-thy- tion. Our synthetic [Phea]deacetyl-thymosin (1
mosin a was essentially the same as that descri- was approximately equal in potency to that of
bed for the purification procedure of [D- our synthetic deacetyl-thymosin a. Interestingly,
Phe(4Br)21]deacetyl-thymosin a. yield 6.9% our synthetic [Phe(4F)21]deacetyl-thymOsin (1
based on the starting resin, [a]21 91.6 (c showed stronger restorative effects than that of
0.4, AcOH), Rf 0.11, Rf
2 0.14, single ninhydrin- our synthetic [Phei]deacetyl-thymosin a.
and chlorine-tolidine positive spot. The synthetic This result encouraged us to synthetize two
peptide exhibited a single spot on a paper elec- deacetyl-thymosin a analogues containing bro-
trophoresis: Toyo Roshi No. 51 (2 x 40 cm), minated Phe or D-Phe residue (position 21)
pyridinium-acetate buffer at pH 7.3, mobility 2.5 which also have an electron-withdrawing effect
cm from the origin toward the anode after on aromatic rings such as fluorinated aromatic
running at 2 mA, 650 V for 90 min. Amino acid rings.
ratios in a 6 N HC1 hydrolysate: Ile 1.00, Ala 3.03, [D-Phe(4Br)i1]deacetyl-thymosin and
Leu 0.97, Val 1.94, Ser 2.89, Thr 2.87, Phe(4Br) [Phei]deacetyl-thymosin (1 were synthetized by
0.96, Asp 3.92, Glu 5.91, Lys 4.02 (recovery of lie the usual solid-phase method starting with Boc-
84%). The synthetic peptide exhibited a single Asn-Merrifield resin. The peptides were con-
peak on HPLC using an analytical YML AM-312 structed on a Merrifield resin by using a single
column (6.0 x 150 mm) at a retention time of coupling reaction for each Boc-amino acid and
12.75 min, when eluted with a gradient of acet- was cleaved from the resin and protecting
onitrile 25 to 45% in 0.1% TFA at a flow rate of 1 groups were also simultaneously deprotected by
ml per min (Fig. 3). FAB-MS m/z: calculated (M treatment with an HF-anisole mixture. Purifica-
+ H) + 3163, observed (M + H) + 3164. tion of the peptides was achieved by gel-filtration
on a Sephadex G-25 column and preparative
E-rosette formation test.. A 5-ml aliquot of venous TLC, and we finally obtained highly purified pep-
blood was drawn into a syringe containing 300 U tides by analytical HPLC. Addition to analytical
heparin and incubated with the synthetic peptide HPLC, integrity of the purified peptides was
for 70 min at 37C. Lymphocytes were then iso- checked by TLC, amino acid analysis after 6 N
lated in a Hypaque-Fioll gradient. Isolated lym- HCl hydrolysis and FAB-MS spectrometry. The
phocyte were adjusted to 5 x 105 cell/ml with relative potencies of the synthetic deacetyl-thymo-
analogues, [Phe(rF) ]deace- PBS: Contamination by monocytes and poly- sin (1 and its three
,21
morphonuclear cells amounted to less than 7%. tyl-thymosin a, [D-Phe(4Br)i1]deacetyl-thymosin
Sheep erythrocytes (Kyokuto Pharmaceutical Co.) a and [Phe(4Br)a]deacetyl-thymosin (1 on
were washed with PBS, and a suspension (1 x restorative effect on the low E-rosette-forming
10v cll/ml)was prepared. The lymphocytes were lymphocytes of uraemic patients are showed in
washed with GVB
2 centrifuged for 10 min at Tables 1 and 2. In contrast to non-uraemics, the
1 500 rpm, and then suspended in GVB
2+ (1 percentage of E-rosette-forming lymphocytes in
ml). The suspension was mixed with the suspen- uraemic patients suffering from recurrent infec-
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Table 1. Effects of synthetic deacetyl-thymosin 1 and its four analogues on the low E-rosette-forming
capacity of lymphocytes of uraemic patients
Peptide Dose No of E-rosette-forming
(lg/ml) determinations lymphocytes
d
(%)
__a 3 76 _-t- 5
II _b 3 35 -t- 4
b,c III deacetyl-thymosin 1 0.1 3 37 _+ 4
IV deacetyl-thymosin 1
b’c 1.0 3 54 -t- 5
b,c V deacetyl-thymosin 1 10.0 3 66 +_ 5
VI [Phe2]deacetyl-thymosin 1
b’c 10.0 3 65 -I- 5
VII [Phe(4F)21]deacetyl-thymosin 1
b’c 0.1 3 57 -t- 5
VIII [Phe(4F)2]deacetyl-thymosin CX,1
b’c 1.0 3 67 -t- 5
b,c IX [Phe($Br)21]deacetyl-thymosin 1 0.2 3 55 -i-_ 4
b,c X [Phe(4Br)21]deacetyl-thymosin cz 2.0 3 65 _-/- 4
Xl [D-Phe(4Br)21]deacetyl-thymosin CZl
b’c 10.0 3 37 -I- 5
Xll [D_Phe(4Br)21]deacetyl_thymosin b.c 20.0 3 36 _--/- 4
aNormal venous blood, bpatient’s venous blood.
Clncubation was carried out at 37C for 70 min.
dEach value represents the mean -t- SD of triplicate measuremetns.
e’l’he significance of differences of mean values was analysed by means of Student’s t-test, p < 0.02 compared with
fThe significance of differences of mean values was analysed by means of Student’s test. p < 0.01 compared with
I1.
Table 2. Relative potencies of the synthetic deacetyl-thymosin
and its analogues on restorative effect on the low E-rosette-
forming lymphocytes of uraemic patients
Peptide Relative potency
(molar basis)
deacetyl-thymosin 1
[Phe21]deacetyl-thymosin 1
[Phe(4F)
21 ]deacetyl-thymosin
[Phe(4Br)
2 ]deacetyl-thymosin
[D-Phe(4Br)
21 ]deacetyl-thymosin
1.00
0.98
10.11
4.86
b
aRelative potencies to deacetyl-thymosin 1 on molar basis.
bNo effect at a dose of 20 Ig/ml.
tious diseases is significantly reduced. Incubation
of lymphocytes from uraemic patients in the pres-
ence of synthetic peptides (0.1-10 btg/ml) or in
the absence of synthetic peptides was carried out
to investigate the recovery of E-rosette-forming
lymphocytes.
Our synthetic [Phe(4Br)21]deacetyl-thymosin
a showed stronger restorative activity than those
of our synthetic deacetyl-thymosin (1 and
[Phe211 deacetyl-thymosin a, but weaker than
that of [Phe(4F)
2 deacetyl-thymosin .
However, our synthetic [D-Phe(4Br)2]deacetyl-
thymosin a had no effect on the low E-rosette-
forming lymphocytes of these patients at a dose
of 20 tg/ml (Table 1).
In conclusion, the present study demonstrates
that electron-withdrawing halogen atoms on the
para position of aromatic rings result in analo-
gues that possess stronger activity than that of
[Phe21] deacetyl-thymosin (1" The analogue
having Phe(4Br) was highly active and its relative
potency was just an intermediate between those
of [Phe(4F)2]deacetyl-thymosin al and deacetyl-
thymosin tl (Table 2). This further indicates that
the electron-withdrawing effect of bromine is
weaker than that of fluorine. Therefore, the
incorporation of bromide atom into the para
position induces a stronger interaction between
Phe
2 and receptor, but it seems to be weaker
than the interaction between the para-fluorinated
phenylalanine
2 and receptor. On the other hand,
the replacement of Phe(4Br) with D-Phe (4Br)
resulted in a sharp reduction in the restorative
effect on the low E-rosette-forming lymphocytes
of uraemic patients. This result would seem to
suggest that the L-type steric configuration at the
21st residue of thymosin a is necessary to
restore immunological activity on the impaired
immunological function.
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